The absence of angiopoietin-2 leads to abnormal vascular maturation and persistent proliferative retinopathy

Thrombosis and Haemostasis

Volumn 102, Issue 1, 2009, Pages 120-130

  Feng, Yuxi ^a   Vom Hagen, Franziska ^a   Wang, Yumei ^a   Beck, Susanne ^b   Schreiter, Kay ^c   Pfister, Frederick ^a   Hoffmann, Sigrid ^a   Wagner, Patrick ^d   Seeliger, Mathias ^b   Molema, Grietje ^e   Deutsch, Urban ^f   Hammes, Hans Peter ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c DeveloGen AG   (Germany)

^d MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Angiogenesis; Angiopoietin; Proliferative retinopathy; VEGF

Indexed keywords

ANGIOPOIETIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL DIAMETER; CONTROLLED STUDY; FLUORESCENCE ANGIOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; PROTEIN ANALYSIS; PROTEIN FUNCTION; RETINA BLOOD VESSEL; RETINA CAPILLARY;

AGE FACTORS; AGING; ANGIOGRAPHY; ANGIOPOIETIN-2; ANIMALS; ANIMALS, NEWBORN; ANOXIA; COLORING AGENTS; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; HUMANS; INDOCYANINE GREEN; INFANT, NEWBORN; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LAC OPERON; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROCIRCULATION; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67749103626     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-09-0567     Document Type: Article

References (31)

1. Frank RN. Diabetic retinopathy. N Engl J Med 2004; 350: 48-58.
2. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006; 26: 859-870.
3. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-936.
4. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997; 277: 48-50.
5. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277: 55-60.
6. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487.
7. Watanabe D, Suzuma K, Suzuma I, et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2005; 139: 476-481.
8. Hammes HP, Lin J, Bretzel RG, et al. Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 1998; 47: 401-406.
9. Hammes HP, Lin J, Wagner P, et al. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes 2004; 53: 1104-1110.
10. Kuroki M, Voest EE, Amano S, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 1996; 98: 1667-1675.
11. Lu M, Kuroki M, Amano S, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 1998; 101: 1219-1224.
12. Yao D, Taguchi T, Matsumura T, et al. High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J Biol Chem 2007; 282: 31038-31045.
13. Feng Y, vom Hagen F, Pfister F, et al. Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression. Thromb Haemost 2007; 97: 99-108.
14. Takagi H, Koyama S, Seike H, et al. Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization. Invest Ophthalmol Vis Sci 2003; 44: 393-402.
15. Umeda N, Ozaki H, Hayashi H, et al. Colocalization of Tie2, angiopoietin 2 and vascular endothelial growth factor in fibrovascular membrane from patients with retinopathy of prematurity. Ophthalmic Res 2003; 35: 217-223.
16. Gale NW, Thurston G, Hackett SF, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 2002; 3: 411-423.
17. Hackett SF, Ozaki H, Strauss RW, et al. Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. J Cell Physiol 2000; 184: 275-284.
18. Hammes HP, Brownlee M, Jonczyk A, et al. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med 1996; 2: 529-533.
19. Seeliger MW, Beck SC, Pereyra-Munoz N, et al. In vivo confocal imaging of the retina in animal models using scanning laser ophthalmoscopy. Vision Res 2005; 45: 3512-3519.
20. Gardiner TA, Gibson DS, de Gooyer TE, et al. Inhibition of tumor necrosis factor-alpha improves physiological angiogenesis and reduces pathological neovascularization in ischemic retinopathy. Am J Pathol 2005; 166: 637-644.
21. Hackett SF, Wiegand S, Yancopoulos G, et al. Angiopoietin-2 plays an important role in retinal angiogenesis. J Cell Physiol 2002; 192: 182-187.
22. Chan CK, Pham LN, Zhou J, et al. Differential expression of pro- and antiangiogenic factors in mouse strain-dependent hypoxia-induced retinal neovascularization. Lab Invest 2005; 85: 721-733.
23. Stalmans I, Ng YS, Rohan R, et al. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest 2002; 109: 327-336.
24. Dixit M, Bess E, Fisslthaler B, et al. Shear stress-induced activation of the AMP-activated protein kinase regulates FoxO1a and angiopoietin-2 in endothelial cells. Cardiovasc Res 2008; 77: 160-168.
25. Pierce EA, Avery RL, Foley ED, et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995; 92: 905-909.
26. Luhmann UF, Lin J, Acar N, et al. Role of the Norrie disease pseudoglioma gene in sprouting angiogenesis during development of the retinal vasculature. Invest Ophthalmol Vis Sci 2005; 46: 3372-3382.
27. Gerhardt H, Golding M, Fruttiger M, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003; 161: 1163-1177.
28. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142: 961-969.
29. Uemura A, Ogawa M, Hirashima M, et al. Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. J Clin Invest 2002; 110: 1619-1628.
30. Thurston G, Rudge JS, Ioffe E, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000; 6: 460-463.
31. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994; 35: 101-111.